Astellas Pharma Inc.
ALPMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $20 | $2,484 | $2,658 | $2,776 |
| - Cash | $2 | $215 | $188 | $180 |
| + Debt | $5 | $889 | $831 | $915 |
| Enterprise Value | $23 | $3,158 | $3,301 | $3,512 |
| Revenue | $4 | $506 | $459 | $517 |
| % Growth | -99.3% | 10.1% | -11.2% | – |
| Gross Profit | $3 | $411 | $382 | $419 |
| % Margin | 73.6% | 81.3% | 83.3% | 81% |
| EBITDA | $1 | $152 | $102 | $126 |
| % Margin | 29.4% | 30% | 22.2% | 24.4% |
| Net Income | $1 | $68 | $75 | -$98 |
| % Margin | 15.1% | 13.5% | 16.3% | -18.9% |
| EPS Diluted | 0.3 | 38.11 | 41.19 | -54.57 |
| % Growth | -99.2% | -7.5% | 175.5% | – |
| Operating Cash Flow | $2 | $55 | $101 | $16 |
| Capital Expenditures | -$0 | -$13 | -$10 | $2 |
| Free Cash Flow | $1 | $42 | $91 | $18 |